Hoogenhout J, Kazem I, Jerusalem C R, Bakkeren J A, de Jong J, Kal H B, van Munster P J
Int J Radiat Oncol Biol Phys. 1983 Jun;9(6):871-9. doi: 10.1016/0360-3016(83)90014-7.
Wistar rats treated with cyclophosphamide, total lymphoid irradiation (TLI), and/or cyclosporin A (CSA) develop a state of immune suppression permitting the growth of tumor xenografts. Experiments were carried out on this newly developed model to investigate the growth patterns of a mouse osteosarcoma and a human colon adenocarcinoma. The combination of cyclophosphamide and CSA permitted a limited period of growth of the mouse osteosarcoma with a tumor take rate of 66%. No takes were observed with the human adenocarcinoma. The combination of cyclophosphamide and TLI resulted in a period of immunosuppression followed by recovery of the immune status. During the period of immunosuppression, tumor xenografts showed a 100% take rate. The most efficient immunosuppression was achieved by a combination of cyclophosphamide, TLI and CSA administered on alternate days. Wistar rats subjected to this treatment showed prolonged tolerance to mouse osteosarcoma and human adenocarcinoma xenografts. There was no alteration in the tumor doubling time or histological morphology of the xenografts in the adapted host as compared with those in the donor tumors. The tumor growth curve showed a pattern of initial growth, a period of stagnation, followed by a steady but slower growth phase. The significance of the results and the advantages of the rat model described in this paper for human tumor xenotransplantation are discussed.
用环磷酰胺、全身淋巴照射(TLI)和/或环孢素A(CSA)处理的Wistar大鼠会出现免疫抑制状态,从而使肿瘤异种移植物得以生长。在此新建立的模型上进行了实验,以研究小鼠骨肉瘤和人结肠腺癌的生长模式。环磷酰胺与CSA联合使用可使小鼠骨肉瘤在有限时间内生长,肿瘤接种成功率为66%。人腺癌未观察到接种成功。环磷酰胺与TLI联合使用会导致一段免疫抑制期,随后免疫状态恢复。在免疫抑制期间,肿瘤异种移植物的接种成功率为100%。通过隔日联合使用环磷酰胺、TLI和CSA可实现最有效的免疫抑制。接受该治疗的Wistar大鼠对小鼠骨肉瘤和人腺癌异种移植物表现出更长时间的耐受性。与供体肿瘤相比,适应宿主中异种移植物的肿瘤倍增时间或组织学形态没有改变。肿瘤生长曲线呈现出初始生长、停滞期,随后是稳定但较慢的生长阶段。本文讨论了结果的意义以及所描述的大鼠模型在人类肿瘤异种移植方面的优势。